NO20015003D0 - Nukleinsyrer kodende for CD40/CD40L kimeriske polypeptider, fremgangsmåter for fremstilling og anvendelse derav - Google Patents

Nukleinsyrer kodende for CD40/CD40L kimeriske polypeptider, fremgangsmåter for fremstilling og anvendelse derav

Info

Publication number
NO20015003D0
NO20015003D0 NO20015003A NO20015003A NO20015003D0 NO 20015003 D0 NO20015003 D0 NO 20015003D0 NO 20015003 A NO20015003 A NO 20015003A NO 20015003 A NO20015003 A NO 20015003A NO 20015003 D0 NO20015003 D0 NO 20015003D0
Authority
NO
Norway
Prior art keywords
preparation
methods
nucleic acids
acids encoding
chimeric polypeptides
Prior art date
Application number
NO20015003A
Other languages
English (en)
Other versions
NO20015003L (no
Inventor
Frank Dicker
Thomas Friess
Gerd Maass
Ulrich Pessara
Werner Scheuer
Stefan Seeber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99107611A external-priority patent/EP1067194A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20015003D0 publication Critical patent/NO20015003D0/no
Publication of NO20015003L publication Critical patent/NO20015003L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20015003A 1999-04-16 2001-10-15 Nukleinsyrer kodende for CD40/CD40L kimeriske polypeptider, fremgangsmåter for fremstilling og anvendelse derav NO20015003L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99107611A EP1067194A1 (en) 1999-04-16 1999-04-16 Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
EP99113967 1999-07-17
PCT/EP2000/003318 WO2000063395A1 (en) 1999-04-16 2000-04-13 Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof

Publications (2)

Publication Number Publication Date
NO20015003D0 true NO20015003D0 (no) 2001-10-15
NO20015003L NO20015003L (no) 2001-10-15

Family

ID=26152970

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015003A NO20015003L (no) 1999-04-16 2001-10-15 Nukleinsyrer kodende for CD40/CD40L kimeriske polypeptider, fremgangsmåter for fremstilling og anvendelse derav

Country Status (8)

Country Link
EP (1) EP1173589A1 (no)
JP (1) JP2003508016A (no)
AR (1) AR023482A1 (no)
AU (1) AU3966200A (no)
CA (1) CA2369820A1 (no)
IL (1) IL144952A0 (no)
NO (1) NO20015003L (no)
WO (1) WO2000063395A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1326896E (pt) 2000-10-02 2011-03-03 Novartis Vaccines & Diagnostic Anticorpos humanos anti-cd40
WO2002036769A2 (en) * 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
WO2005044304A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
CA2544852A1 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
PL1682178T3 (pl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Sposoby terapii nowotworów wykazujących ekspresje antygenu CD40
EP2243492A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
US20070098718A1 (en) 2003-11-04 2007-05-03 Chiron Methods of therapy for b cell-related cancers
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
AU2007240507B2 (en) 2006-04-21 2013-07-18 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
EP2066339B1 (en) 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
AU2008318615A1 (en) 2007-10-30 2009-05-07 Texas A&M University System Compositions and methods of enhancing immune responses to flagellated bacterium
PT3097926T (pt) 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
JP5568807B2 (ja) * 2008-06-06 2014-08-13 静岡県 プロテオミクス解析を用いたメラノーママーカーの同定
WO2011091255A1 (en) 2010-01-21 2011-07-28 The Board Of Trustees Of The University Of Arkansas Vaccine vectors and methods of enhancing immune responses
WO2011156619A2 (en) 2010-06-09 2011-12-15 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
CN105142665A (zh) 2013-02-14 2015-12-09 阿肯色大学评议会 增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR20230070521A (ko) 2016-05-03 2023-05-23 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
WO2018094309A2 (en) 2016-11-21 2018-05-24 Nant Holdings Ip, Llc Fractal combination therapy
WO2019241592A1 (en) * 2018-06-14 2019-12-19 Nantbio, Inc. Tnf-type receptor-ligand fusion proteins and methods
US20210369825A1 (en) * 2018-10-05 2021-12-02 Nantcell, Inc. Cd40 and cd40l combo in an adv vaccine vehicle

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233402T3 (de) * 1991-10-25 2009-06-25 Immunex Corp., Seattle Neue cytokine
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells

Also Published As

Publication number Publication date
WO2000063395A1 (en) 2000-10-26
AR023482A1 (es) 2002-09-04
CA2369820A1 (en) 2000-10-26
AU3966200A (en) 2000-11-02
IL144952A0 (en) 2002-06-30
EP1173589A1 (en) 2002-01-23
NO20015003L (no) 2001-10-15
JP2003508016A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
NO20015003L (no) Nukleinsyrer kodende for CD40/CD40L kimeriske polypeptider, fremgangsmåter for fremstilling og anvendelse derav
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
WO2003023008A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
NO20024774L (no) [1,4`]-bipiperidinforbindelsr, fremgangsmate til fremstilling derav og anvendelse dera, farmasoytisk preparat, samt mellomprodukter
AU2002221780A1 (en) Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1576169A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME, AND METHODS OF USE THEREOF
AU9633301A (en) Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
EP1487864A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES AND METHODS OF USE THEREOF
AU2002356534A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1446419A4 (en) THERAPEUTIC POLYPEPTIDES FOR THOSE CODING NUCLEIC ACIDS AND METHOD OF ADMINISTRATION
EP1432726A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS CODED FOR THEM, AND METHOD OF USE
EP1401858A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS COATING THEREOF AND METHOD OF USE
AU2003217956A8 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
EP1695078A4 (en) METADHERINE POLYPEPTIDES, CODING NUCLEIC ACIDS AND METHOD OF USE
AU2003247537A8 (en) Chd5 encoding nucleic acids, polypeptides, antibodies and methods of use thereof
EP1532238A4 (en) THERAPEUTIC POLYPEPTIDES, THESE CODING NUCLEIC ACIDS AND METHOD OF USE
EP1539985A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES, AND METHODS OF USE
AU2002365905A8 (en) Transaminases, nucleic acids encoding them and methods of making and using them
EP1399537A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THEM, AND METHODS OF USE
EP1443913A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES AND METHODS OF USE THEREOF
EP1549671A4 (en) THERAPEUTIC POLYPEPTIDES, THESE CODING NUCLEIC CAUSE, AND USE PROCESS
AU2002365216A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2003304034A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003060149A9 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2003270424A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application